losartan has been researched along with Disease Exacerbation in 112 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Long-term outcome of Marfan syndrome patients randomly assigned to losartan or atenolol showed no differences in aortic dilation rate or presence of clinical events between treatment groups." | 9.27 | Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. ( Evangelista, A; Forteza, A; García-Dorado, D; González Mirelis, J; Gutiérrez, L; Ibáñez, B; Rodríguez-Palomares, J; Sánchez, V; Teixido-Tura, G, 2018) |
| "Patients with idiopathic pulmonary fibrosis and a baseline %FVC of ≥50 % were treated with losartan 50 mg by mouth daily for 12 months." | 9.16 | Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. ( Couluris, M; Gross-King, M; Kinder, BW; Krischer, J; Panos, RJ; Xu, P, 2012) |
| "73 m(2) and proteinuria with protein greater than 500 mg/g of creatinine on treatment with losartan, 100 mg/d, for longer than 6 months were screened in National Taiwan University Hospital." | 9.13 | Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 9.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "A total of 754 hypertensive patients with left ventricular hypertrophy (LVH) by Cornell voltage-duration product or Sokolow-Lyon voltage criteria on a screening electrocardiogram had their LV mass measured by echocardiogram at enrolment in the Losartan Intervention For Endpoint Reduction (LIFE) trial, and after 12 and 24 months of blinded therapy with losartan-based or atenolol-based regimens." | 9.10 | Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Liu, JE; Nieminen, MS; Palmieri, V; Papademetriou, V; Wachtell, K, 2002) |
| "The results suggest that losartan and enalapril are of comparable efficacy and tolerability in the short-term treatment of moderate or severe congestive heart failure." | 9.08 | Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. ( Chang, P; Dickstein, K; Hall, C; Haunsø, S; Kjekshus, J; Remes, J; Willenheimer, R, 1995) |
| "We assessed the ability of poststroke losartan and captopril treatment to attenuate hematoma expansion and plasma extravasation after intracerebral hemorrhagic stroke in Kyoto-Wistar stroke-prone hypertensive rats (SHRsp)." | 7.88 | Post-stroke losartan and captopril treatments arrest hemorrhagic expansion in SHRsp without lowering blood pressure. ( Negandhi, A; Smeda, JS; Stuckless, J; Watson, D, 2018) |
| " To test this hypothesis, we investigated the therapeutic effects of a combination of donepezil and losartan in CHF rats with extensive myocardial infarction (MI)." | 7.80 | Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure. ( Inagaki, M; Kawada, T; Li, M; Sugimachi, M; Uemura, K; Zheng, C, 2014) |
| "Twenty-one days after induction, losartan significantly improved the macro- and microscopic scores of fibrosis in the colonic wall and reduced TGF-b1 concentration." | 7.78 | Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. ( Goldin, E; Israeli, E; Latella, G; Lysy, J; Metanes, I; Necozione, S; Papo, O; Pines, M; Wengrower, D; Zanninelli, G, 2012) |
| "Angiotensin II (AngII) mediates progression of aortic aneurysm, but the relative contribution of its type 1 (AT1) and type 2 (AT2) receptors remains unknown." | 7.77 | Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. ( Aziz, H; Bedja, D; Chen, Y; Dietz, HC; Doyle, JJ; Habashi, JP; Holm, TM; Judge, DP; Modiri, AN; Schoenhoff, F, 2011) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 7.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| " The purpose of the present study was to examine the effect of losartan, an angiotensin-II receptor antagonist, on the progression of advanced renal insufficiency." | 7.73 | Losartan, an angiotensin-II receptor antagonist, retards the progression of advanced renal insufficiency. ( Fujita, T; Kumasaka, R; Murakami, R; Nakamura, M; Nakamura, N; Okumura, K; Osawa, H; Shimada, M; Shirato, K; Yamabe, H, 2006) |
| "Losartan treatment partially attenuated these responses." | 5.40 | Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy. ( He, P; Li, D; Zhang, B, 2014) |
| "Losartan was well tolerated and demonstrated significant anti-proteinuric effects in patients with T2DM with early nephropathy independent of hypertension, warranting further long-term large-scale studies to prove its usefulness as preventive therapy for diabetic nephropathy." | 5.34 | Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus. ( Agha, A; Anwar, E; Bashir, K, 2007) |
| "Long-term outcome of Marfan syndrome patients randomly assigned to losartan or atenolol showed no differences in aortic dilation rate or presence of clinical events between treatment groups." | 5.27 | Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. ( Evangelista, A; Forteza, A; García-Dorado, D; González Mirelis, J; Gutiérrez, L; Ibáñez, B; Rodríguez-Palomares, J; Sánchez, V; Teixido-Tura, G, 2018) |
| "Patients with idiopathic pulmonary fibrosis and a baseline %FVC of ≥50 % were treated with losartan 50 mg by mouth daily for 12 months." | 5.16 | Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. ( Couluris, M; Gross-King, M; Kinder, BW; Krischer, J; Panos, RJ; Xu, P, 2012) |
| " Data from the Renoprotection of Optimal Antiproteinuric Doses (ROAD) trial were used to examine the contribution of the antiproteinuric effect of benazepril and losartan on renal outcome (the primary composite end point of doubling of serum creatinine and end-stage renal disease or death) in 339 Chinese nondiabetic CKD patients with overt proteinuria and renal insufficiency." | 5.15 | High level of proteinuria during treatment with renin-angiotensin inhibitors is a strong predictor of renal outcome in nondiabetic kidney disease. ( Fu, BL; Hou, FF; Liang, M; Xie, D; Zhang, X, 2011) |
| "We conducted a multicenter, controlled trial involving 285 normotensive patients with type 1 diabetes and normoalbuminuria and who were randomly assigned to receive losartan (100 mg daily), enalapril (20 mg daily), or placebo and followed for 5 years." | 5.14 | Renal and retinal effects of enalapril and losartan in type 1 diabetes. ( Donnelly, S; Drummond, K; Gardiner, R; Goodyer, P; Gubler, MC; Klein, R; Mauer, M; Sinaiko, A; Strand, T; Suissa, S; Zinman, B, 2009) |
| "73 m(2) and proteinuria with protein greater than 500 mg/g of creatinine on treatment with losartan, 100 mg/d, for longer than 6 months were screened in National Taiwan University Hospital." | 5.13 | Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 5.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| " Treatment with losartan is associated with a reduction in proteinuria, a delay in the onset of ESRD, and no increased risk of cardiovascular events in this pre-ESRD population." | 5.11 | Losartan and end-organ protection--lessons from the RENAAL study. ( Brenner, BM; Dickson, TZ; Kowey, PR; Shahinfar, S; Zhang, Z, 2005) |
| "A total of 754 hypertensive patients with left ventricular hypertrophy (LVH) by Cornell voltage-duration product or Sokolow-Lyon voltage criteria on a screening electrocardiogram had their LV mass measured by echocardiogram at enrolment in the Losartan Intervention For Endpoint Reduction (LIFE) trial, and after 12 and 24 months of blinded therapy with losartan-based or atenolol-based regimens." | 5.10 | Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Liu, JE; Nieminen, MS; Palmieri, V; Papademetriou, V; Wachtell, K, 2002) |
| "We studied 659 participants in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study with both electrocardiographic and echocardiographic LV hypertrophy (68% of the echocardiographic cohort) without previous myocardial infarction." | 5.09 | Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. ( Bella, JN; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Nieminen, MS; Palmieri, V; Papademetriou, V; Tuxen, C; Wachtell, K, 2001) |
| "The results suggest that losartan and enalapril are of comparable efficacy and tolerability in the short-term treatment of moderate or severe congestive heart failure." | 5.08 | Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. ( Chang, P; Dickstein, K; Hall, C; Haunsø, S; Kjekshus, J; Remes, J; Willenheimer, R, 1995) |
| "We assessed the ability of poststroke losartan and captopril treatment to attenuate hematoma expansion and plasma extravasation after intracerebral hemorrhagic stroke in Kyoto-Wistar stroke-prone hypertensive rats (SHRsp)." | 3.88 | Post-stroke losartan and captopril treatments arrest hemorrhagic expansion in SHRsp without lowering blood pressure. ( Negandhi, A; Smeda, JS; Stuckless, J; Watson, D, 2018) |
| "This study confirms that angiotensin II type 1 receptor antagonism (losartan) decreases aortic aneurysm growth in a mouse model of MFS." | 3.88 | The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome. ( Clijsters, M; Herijgers, P; Meuris, B; Schepens, J; Verbrugghe, P; Verhoeven, J; Vervoort, D, 2018) |
| "A multistate model to predict HF hospitalization and all-cause mortality was derived using data (n=3834) from the HEAAL study (Heart Failure Endpoint evaluation of Angiotensin II Antagonist Losartan), a multinational randomized trial in symptomatic patients with reduced left ventricular ejection fraction." | 3.83 | Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation. ( Huggins, GS; Kent, DM; Klaveren, Dv; Konstam, MA; Noubary, F; Upshaw, JN, 2016) |
| " To test this hypothesis, we investigated the therapeutic effects of a combination of donepezil and losartan in CHF rats with extensive myocardial infarction (MI)." | 3.80 | Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure. ( Inagaki, M; Kawada, T; Li, M; Sugimachi, M; Uemura, K; Zheng, C, 2014) |
| "Twenty-one days after induction, losartan significantly improved the macro- and microscopic scores of fibrosis in the colonic wall and reduced TGF-b1 concentration." | 3.78 | Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. ( Goldin, E; Israeli, E; Latella, G; Lysy, J; Metanes, I; Necozione, S; Papo, O; Pines, M; Wengrower, D; Zanninelli, G, 2012) |
| "Angiotensin II (AngII) mediates progression of aortic aneurysm, but the relative contribution of its type 1 (AT1) and type 2 (AT2) receptors remains unknown." | 3.77 | Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. ( Aziz, H; Bedja, D; Chen, Y; Dietz, HC; Doyle, JJ; Habashi, JP; Holm, TM; Judge, DP; Modiri, AN; Schoenhoff, F, 2011) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 3.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "(1) Some angiotensin-converting-enzyme inhibitors (ACE inhibitors) reduce mortality in patients with heart failure (captopril, enalapril, ramipril and trandolapril), and in patients with recent myocardial infarction and heart failure or marked left ventricular dysfunction (captopril, ramipril and trandolapril)." | 3.73 | Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. ( , 2005) |
| " The purpose of the present study was to examine the effect of losartan, an angiotensin-II receptor antagonist, on the progression of advanced renal insufficiency." | 3.73 | Losartan, an angiotensin-II receptor antagonist, retards the progression of advanced renal insufficiency. ( Fujita, T; Kumasaka, R; Murakami, R; Nakamura, M; Nakamura, N; Okumura, K; Osawa, H; Shimada, M; Shirato, K; Yamabe, H, 2006) |
| "This article presents clinical data which suggest that the current dosage of losartan 50 to 100 mg/day may not be the optimum in many cases, especially if used as monotherapy in the treatment of proteinuria and we may have to increase to 200 mg/day." | 3.73 | ATRA therapy restores normal renal function and renal reserve and prevents renal failure. ( Chan, CM; Lau, YK; Wong, KS; Woo, KT, 2005) |
| "In American Indians with type 2 diabetes and preserved GFR at baseline, increasing ACR reflects the progression of earlier structural glomerular lesions, whereas early GFR decline may not accurately reflect such lesions." | 2.90 | Changes in Albuminuria But Not GFR are Associated with Early Changes in Kidney Structure in Type 2 Diabetes. ( Boustany-Kari, CM; Esplin, CA; Guarnieri, P; Harder, JL; Hill, J; Kretzler, M; Looker, HC; Mauer, M; Nair, V; Najafian, B; Nelson, RG; Saulnier, PJ, 2019) |
| "Treatment with losartan had no effect on cardiac function or exercise capacity compared with placebo." | 2.82 | Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial. ( Axelsson, A; Bundgaard, H; Havndrup, O; Ho, CY; Iversen, K; Jensen, M; Kofoed, KF; Norsk, J; Vejlstrup, N, 2016) |
| "In patients with proteinuric diabetic kidney disease, mean systolic BP ≥ 140 mmHg and mean diastolic BP ≥ 80 mmHg were associated with worse renal outcomes." | 2.80 | BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial. ( Emanuele, NV; Fried, LF; Guarino, P; Leehey, DJ; Palevsky, PM; Reilly, RF; Whaley-Connell, A; Zhang, JH, 2015) |
| "In this cohort of patients with type 2 diabetes with nephropathy, serum bicarbonate level associations with kidney disease end points were not retained after adjustment for estimated glomerular filtration rate, which is in contrast to results of earlier studies in nondiabetic populations." | 2.80 | Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St ( Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH, 2015) |
| "Proteinuria is a common presentation of mesangioproliferative glomerulonephritis (MsPGN)." | 2.76 | Renin-angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10 year follow-up. ( Caglioti, C; Casoria, V; Comi, N; Conte, G; Fuiano, G; Fuiano, L; Iodice, C; Minutolo, R; Presta, P, 2011) |
| "The reduction in the number of ESRD days over 4 years in patients treated with losartan significantly decreased costs associated with ESRD by 7,438 euros per patient (CI 95%: 3,029 euros - 11,847 euros, p=0." | 2.71 | An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. ( Durand Zaleski, I; Gaugris, S; Hannedouche, T; Passa, P; Rodier, M; Souchet, T, 2003) |
| "After adjustment for predictors of ESRD, the hazard ratios for the first, second, and third Hb quartiles were 1." | 2.71 | Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Keane, WF; Mohanram, A; Shahinfar, S; Toto, RD; Zhang, Z, 2004) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | 2.70 | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001) |
| "The dystrophinopathies include Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and X-linked dilated cardiomyopathy (XLDCM)." | 2.58 | Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. ( Bourke, JP; Bueser, T; Quinlivan, R, 2018) |
| "Thoracic aortic aneurysm is a major health problem with multiple causes and potentially devastating consequences." | 2.46 | Is losartan the true panacea for aneurysm disease? CON. ( Danyi, P; Jovin, IS, 2010) |
| "The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study was conducted from 1996 to 2001." | 2.43 | Losartan: lessons learned from the RENAAL study. ( Brenner, BM; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2006) |
| "Diabetes (particularly type 2 diabetes) represents a global health problem of epidemic proportions." | 2.43 | Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. ( Burnier, M; Zanchi, A, 2006) |
| "Proteinuria is a sign of established kidney damage and plays a direct pathogenic role in the progression of renal and cardiovascular disease." | 2.43 | Time to abandon microalbuminuria? ( Remuzzi, G; Ruggenenti, P, 2006) |
| "Losartan treatment partially attenuated these responses." | 1.40 | Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy. ( He, P; Li, D; Zhang, B, 2014) |
| "Treatment with bisoprolol slowed the heart rate, and treatment with losartan lowered mean arterial pressure, confirming adequate dosing, but none of the treatments improved RV function or arrested the progression of RV hypertrophy and failure compared with vehicle." | 1.40 | Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart. ( Andersen, A; Andersen, S; Bogaard, HJ; de Man, FS; Holmboe, S; Nielsen, JM; Nielsen-Kudsk, JE; Ringgaard, S; Schultz, JG; Vildbrad, MD; Vonk-Noordegraaf, A, 2014) |
| "AGTR1 protein was detected in 86% of ovarian cancer tissues, while AGTR2 was not detected in immunohistochemistry." | 1.40 | Dual targeting of angiotensin receptors (AGTR1 and AGTR2) in epithelial ovarian carcinoma. ( Bae, DS; Cho, YJ; Choi, CH; Choi, JJ; Do, IG; Jeon, HK; Kim, BG; Kim, TJ; Lee, JK; Lee, JW; Lee, YY; Park, YA; Ryu, JY; Song, SY, 2014) |
| "ARB markedly inhibited liver fibrosis development along with suppression of the number of Ac-HSC and TGF-β." | 1.39 | Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. ( Aihara, Y; Douhara, A; Fukui, H; Kaji, K; Kawaratani, H; Moriya, K; Namisaki, T; Noguchi, R; Shirai, Y; Yoshiji, H, 2013) |
| "Losartan has been shown to prevent aneurysms in another mouse model of MFS, Fbn1(C1039G/+), through inhibition of the Erk1/2 pathway." | 1.38 | MMP-2 regulates Erk1/2 phosphorylation and aortic dilatation in Marfan syndrome. ( Baxter, BT; Knispel, R; Meisinger, T; Worth, JM; Xiong, W, 2012) |
| "Patients with idiopathic pulmonary arterial hypertension (iPAH) often have a low cardiac output." | 1.38 | Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. ( Boonstra, A; de Man, FS; Dorfmüller, P; Eddahibi, S; Fadel, E; François, C; Guignabert, C; Handoko, ML; Humbert, M; Perros, F; Postmus, PE; Rain, S; Ruiter, G; Schalij, I; Simonneau, G; Tu, L; van der Velden, J; Vonk-Noordegraaf, A, 2012) |
| "To test this strategy in a model of type 2 diabetes, we treated 2-month-old diabetic Lprdb/db mice with losartan, paricalcitol, or a combination of losartan and paricalcitol for 3 months." | 1.36 | Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. ( Chang, A; Deb, DK; Kong, J; Li, YC; Ning, G; Shi, H; Sun, T; Wong, KE; Zhang, Y; Zhang, Z, 2010) |
| "Rats with advanced liver fibrosis due to prolonged bile duct ligation or carbon tetrachloride administration were treated with daily doses of saline, losartan-M6PHSA, M6PHSA or oral losartan during 3 days." | 1.36 | Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. ( Arroyo, V; Bataller, R; Beljaars, L; Brenner, DA; Fondevila, C; Ginès, P; Gonzalo, T; Kok, RJ; Lacombe, M; Moreno, M; Poelstra, K; Prakash, J; Sancho-Bru, P; Swart, J; Temming, K; van Beuge, M; van der Hoeven, P, 2010) |
| "Marfan's syndrome is a genetic disorder affecting connective tissues, and it can lead to death due to aortic defects if left untreated." | 1.35 | Targeting TGF-beta and the extracellular matrix in Marfan's syndrome. ( Han, Y; Kalluri, R, 2008) |
| "Uremia was induced in apoE-/- mice by 5/6 nephrectomy (NX)." | 1.34 | Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice. ( Binder, CJ; Bro, S; Nielsen, LB; Olgaard, K; Witztum, JL, 2007) |
| "Losartan was well tolerated and demonstrated significant anti-proteinuric effects in patients with T2DM with early nephropathy independent of hypertension, warranting further long-term large-scale studies to prove its usefulness as preventive therapy for diabetic nephropathy." | 1.34 | Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus. ( Agha, A; Anwar, E; Bashir, K, 2007) |
| "Losartan was excellently tolerated in all patients in group A." | 1.33 | Effect of losartan on slowing progression of chronic allograft nephropathy. ( Fan, MQ; Fang, ZQ; Feng, JY; Huang, CB; Wang, PX; Xiao, Y; Zhang, YP, 2005) |
| "The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) Study evaluated the renal protective effects of losartan versus placebo on a background of non-ACE-I/non-AIIA conventional antihypertensive therapy in 1513 patients with type 2 diabetes and nephropathy." | 1.31 | Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. ( Brenner, B; Carides, GW; Gerth, WC; Hannedouche, T; Martinez-Castelao, A; Remuzzi, G; Shahinfar, S; Viberti, G, 2002) |
| "We report a case of IgA nephropathy with renal failure in which the deterioration of renal function was inhibited by the addition of angiotensin II receptor blocker (ARB) losartan." | 1.31 | Progression of renal failure delayed by use of losartan in a case of IgA nephropathy. ( Iseki, K; Takishita, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.79) | 18.2507 |
| 2000's | 53 (47.32) | 29.6817 |
| 2010's | 56 (50.00) | 24.3611 |
| 2020's | 1 (0.89) | 2.80 |
| Authors | Studies |
|---|---|
| Wise, RA | 1 |
| Holbrook, JT | 1 |
| Brown, RH | 1 |
| Criner, GJ | 1 |
| Dransfield, MT | 1 |
| He, J | 1 |
| Henderson, RJ | 1 |
| Kaminsky, DA | 1 |
| Kaner, RJ | 1 |
| Lazarus, SC | 1 |
| Make, BJ | 1 |
| McCormack, MC | 1 |
| Neptune, ER | 1 |
| Que, LG | 1 |
| Coulson, R | 1 |
| Liew, SH | 1 |
| Connelly, AA | 1 |
| Yee, NS | 1 |
| Deb, S | 1 |
| Kumar, B | 1 |
| Vargas, AC | 1 |
| O'Toole, SA | 1 |
| Parslow, AC | 1 |
| Poh, A | 1 |
| Putoczki, T | 1 |
| Morrow, RJ | 1 |
| Alorro, M | 1 |
| Lazarus, KA | 1 |
| Yeap, EFW | 1 |
| Walton, KL | 1 |
| Harrison, CA | 1 |
| Hannan, NJ | 1 |
| George, AJ | 1 |
| Clyne, CD | 1 |
| Ernst, M | 1 |
| Allen, AM | 1 |
| Chand, AL | 1 |
| Wang, T | 2 |
| Gao, W | 1 |
| Xiao, K | 1 |
| Liu, Q | 2 |
| Jia, R | 2 |
| Kehoe, PG | 1 |
| Blair, PS | 1 |
| Howden, B | 1 |
| Thomas, DL | 1 |
| Malone, IB | 1 |
| Horwood, J | 1 |
| Clement, C | 1 |
| Selman, LE | 1 |
| Baber, H | 1 |
| Lane, A | 1 |
| Coulthard, E | 1 |
| Passmore, AP | 1 |
| Fox, NC | 1 |
| Wilkinson, IB | 1 |
| Ben-Shlomo, Y | 1 |
| Montes-Rivera, JO | 1 |
| Tamay-Cach, F | 1 |
| Quintana-Pérez, JC | 1 |
| Guevara-Salazar, JA | 1 |
| Trujillo-Ferrara, JG | 1 |
| Del Valle-Mondragón, L | 1 |
| Arellano-Mendoza, MG | 1 |
| Verbrugghe, P | 1 |
| Verhoeven, J | 1 |
| Clijsters, M | 1 |
| Vervoort, D | 1 |
| Schepens, J | 1 |
| Meuris, B | 1 |
| Herijgers, P | 1 |
| Roy, S | 1 |
| Rai, P | 1 |
| Eiymo Mwa Mpollo, MS | 1 |
| Chang, KH | 1 |
| Rizvi, T | 1 |
| Shanmukhappa, SK | 1 |
| VandenHeuvel, K | 1 |
| Aronow, B | 1 |
| Inagami, T | 1 |
| Cancelas, JA | 1 |
| Malik, P | 1 |
| Smeda, JS | 1 |
| Watson, D | 1 |
| Stuckless, J | 1 |
| Negandhi, A | 1 |
| Teixido-Tura, G | 1 |
| Forteza, A | 1 |
| Rodríguez-Palomares, J | 1 |
| González Mirelis, J | 1 |
| Gutiérrez, L | 1 |
| Sánchez, V | 1 |
| Ibáñez, B | 1 |
| García-Dorado, D | 1 |
| Evangelista, A | 1 |
| Bourke, JP | 1 |
| Bueser, T | 1 |
| Quinlivan, R | 1 |
| Thomas, M | 1 |
| Fronk, Z | 1 |
| Gross, A | 1 |
| Willmore, D | 1 |
| Arango, A | 1 |
| Higham, C | 1 |
| Nguyen, V | 1 |
| Lim, H | 1 |
| Kale, V | 1 |
| McMillan, G | 1 |
| Seegmiller, RE | 1 |
| Shree, J | 1 |
| Choudhary, R | 1 |
| Bodakhe, SH | 1 |
| Alvarez, M | 1 |
| Ardiles, L | 1 |
| Looker, HC | 1 |
| Mauer, M | 2 |
| Saulnier, PJ | 2 |
| Harder, JL | 1 |
| Nair, V | 1 |
| Boustany-Kari, CM | 1 |
| Guarnieri, P | 1 |
| Hill, J | 1 |
| Esplin, CA | 1 |
| Kretzler, M | 1 |
| Nelson, RG | 2 |
| Najafian, B | 1 |
| Ohta, Y | 1 |
| Kawano, Y | 1 |
| Iwashima, Y | 1 |
| Hayashi, S | 1 |
| Yoshihara, F | 1 |
| Matayoshi, T | 1 |
| Takiuchi, S | 1 |
| Kamide, K | 1 |
| Nakamura, S | 1 |
| Horio, T | 1 |
| Elshershari, H | 1 |
| Harris, C | 1 |
| Gallo, EM | 1 |
| Loch, DC | 1 |
| Habashi, JP | 3 |
| Calderon, JF | 1 |
| Chen, Y | 3 |
| Bedja, D | 3 |
| van Erp, C | 2 |
| Gerber, EE | 1 |
| Parker, SJ | 1 |
| Sauls, K | 1 |
| Judge, DP | 3 |
| Cooke, SK | 1 |
| Lindsay, ME | 2 |
| Rouf, R | 1 |
| Myers, L | 1 |
| ap Rhys, CM | 1 |
| Kent, KC | 1 |
| Norris, RA | 1 |
| Huso, DL | 1 |
| Dietz, HC | 3 |
| Huang, MM | 1 |
| Guo, AB | 1 |
| Sun, JF | 1 |
| Chen, XL | 1 |
| Yin, ZY | 1 |
| He, P | 1 |
| Li, D | 1 |
| Zhang, B | 1 |
| Yu, H | 1 |
| Liu, B | 1 |
| Park, YA | 1 |
| Choi, CH | 1 |
| Do, IG | 1 |
| Song, SY | 1 |
| Lee, JK | 1 |
| Cho, YJ | 1 |
| Choi, JJ | 1 |
| Jeon, HK | 1 |
| Ryu, JY | 1 |
| Lee, YY | 1 |
| Kim, TJ | 1 |
| Bae, DS | 1 |
| Lee, JW | 1 |
| Kim, BG | 1 |
| Andersen, S | 1 |
| Schultz, JG | 1 |
| Andersen, A | 1 |
| Ringgaard, S | 1 |
| Nielsen, JM | 1 |
| Holmboe, S | 1 |
| Vildbrad, MD | 1 |
| de Man, FS | 2 |
| Bogaard, HJ | 1 |
| Vonk-Noordegraaf, A | 2 |
| Nielsen-Kudsk, JE | 1 |
| Li, M | 1 |
| Zheng, C | 1 |
| Kawada, T | 1 |
| Inagaki, M | 1 |
| Uemura, K | 1 |
| Sugimachi, M | 1 |
| Yan, W | 1 |
| Li, J | 2 |
| Chai, R | 1 |
| Guo, W | 1 |
| Xu, L | 2 |
| Han, Y | 2 |
| Bai, X | 1 |
| Wang, H | 2 |
| Cook, JR | 1 |
| Clayton, NP | 1 |
| Carta, L | 1 |
| Galatioto, J | 1 |
| Chiu, E | 1 |
| Smaldone, S | 1 |
| Nelson, CA | 1 |
| Cheng, SH | 1 |
| Wentworth, BM | 1 |
| Ramirez, F | 1 |
| Schutte, E | 1 |
| Lambers Heerspink, HJ | 1 |
| Lutgers, HL | 1 |
| Bakker, SJ | 1 |
| Vart, P | 1 |
| Wolffenbuttel, BH | 1 |
| Umanath, K | 1 |
| Lewis, JB | 1 |
| de Zeeuw, D | 2 |
| Gansevoort, RT | 1 |
| Mehrotra, P | 1 |
| Patel, JB | 1 |
| Ivancic, CM | 1 |
| Collett, JA | 1 |
| Basile, DP | 1 |
| Lüscher, TF | 1 |
| Chen, R | 1 |
| Mian, M | 1 |
| Fu, M | 1 |
| Zhao, JY | 1 |
| Yang, L | 1 |
| Li, Y | 1 |
| Leehey, DJ | 1 |
| Zhang, JH | 2 |
| Emanuele, NV | 1 |
| Whaley-Connell, A | 1 |
| Palevsky, PM | 2 |
| Reilly, RF | 1 |
| Guarino, P | 1 |
| Fried, LF | 2 |
| Axelsson, A | 1 |
| Iversen, K | 1 |
| Vejlstrup, N | 1 |
| Ho, CY | 1 |
| Havndrup, O | 1 |
| Kofoed, KF | 1 |
| Norsk, J | 1 |
| Jensen, M | 1 |
| Bundgaard, H | 1 |
| Anan, HH | 1 |
| Zidan, RA | 1 |
| Shaheen, MA | 1 |
| Abd-El Fattah, EA | 1 |
| Upshaw, JN | 1 |
| Konstam, MA | 1 |
| Klaveren, Dv | 1 |
| Noubary, F | 1 |
| Huggins, GS | 1 |
| Kent, DM | 1 |
| Tanamas, SK | 1 |
| Fufaa, GD | 1 |
| Wheelock, KM | 1 |
| Weil, EJ | 1 |
| Hanson, RL | 1 |
| Knowler, WC | 1 |
| Bennett, PH | 1 |
| Matsushima, T | 1 |
| Nakajima, H | 1 |
| Ohko, K | 1 |
| Nakajima, K | 1 |
| Sano, S | 1 |
| Crespo, MJ | 2 |
| Cruz, N | 1 |
| Altieri, PI | 2 |
| Escobales, N | 2 |
| Kalluri, R | 1 |
| Lin, SL | 1 |
| Chen, YM | 1 |
| Chiang, WC | 1 |
| Wu, KD | 1 |
| Tsai, TJ | 1 |
| Mihailovic-Stanojevic, N | 1 |
| Jovovic, D | 1 |
| Miloradovic, Z | 1 |
| Grujic-Milanovic, J | 1 |
| Jerkic, M | 1 |
| Markovic-Lipkovski, J | 1 |
| Perico, N | 2 |
| Cattaneo, D | 1 |
| Remuzzi, G | 5 |
| Duckworth, W | 1 |
| O'Connor, T | 1 |
| Brophy, M | 1 |
| Emanuele, N | 1 |
| Huang, GD | 1 |
| McCullough, PA | 1 |
| Seliger, S | 1 |
| Warren, SR | 1 |
| Peduzzi, P | 1 |
| Müller, D | 1 |
| Müller, DN | 1 |
| Gambarin, FI | 1 |
| Favalli, V | 1 |
| Serio, A | 1 |
| Regazzi, M | 1 |
| Pasotti, M | 1 |
| Klersy, C | 1 |
| Dore, R | 1 |
| Mannarino, S | 1 |
| Viganò, M | 1 |
| Odero, A | 1 |
| Amato, S | 1 |
| Tavazzi, L | 1 |
| Arbustini, E | 1 |
| Zinman, B | 1 |
| Gardiner, R | 1 |
| Suissa, S | 1 |
| Sinaiko, A | 1 |
| Strand, T | 1 |
| Drummond, K | 1 |
| Donnelly, S | 1 |
| Goodyer, P | 1 |
| Gubler, MC | 1 |
| Klein, R | 1 |
| Desbuards, N | 1 |
| Hyvelin, JM | 1 |
| Machet, MC | 1 |
| Eder, V | 1 |
| Garrigue, MA | 1 |
| Halimi, JM | 1 |
| Antier, D | 1 |
| Zoja, C | 1 |
| Corna, D | 1 |
| Rottoli, D | 1 |
| Gaspari, F | 1 |
| Haskell, L | 1 |
| Delea, TE | 1 |
| Sofrygin, O | 1 |
| Palmer, JL | 1 |
| Lau, H | 1 |
| Munk, VC | 1 |
| Sung, J | 1 |
| Charney, A | 1 |
| Parving, HH | 2 |
| Sullivan, SD | 1 |
| Moreno, M | 1 |
| Gonzalo, T | 1 |
| Kok, RJ | 1 |
| Sancho-Bru, P | 1 |
| van Beuge, M | 1 |
| Swart, J | 1 |
| Prakash, J | 1 |
| Temming, K | 1 |
| Fondevila, C | 1 |
| Beljaars, L | 1 |
| Lacombe, M | 1 |
| van der Hoeven, P | 1 |
| Arroyo, V | 1 |
| Poelstra, K | 1 |
| Brenner, DA | 1 |
| Ginès, P | 1 |
| Bataller, R | 1 |
| Deb, DK | 1 |
| Sun, T | 1 |
| Wong, KE | 1 |
| Zhang, Z | 6 |
| Ning, G | 1 |
| Zhang, Y | 1 |
| Kong, J | 1 |
| Shi, H | 1 |
| Chang, A | 1 |
| Li, YC | 1 |
| Danyi, P | 1 |
| Jovin, IS | 1 |
| Deng, JL | 1 |
| Yue, J | 1 |
| Hou, YB | 1 |
| Agarwal, R | 1 |
| Titan, SM | 1 |
| Zatz, R | 1 |
| Graciolli, FG | 1 |
| dos Reis, LM | 1 |
| Barros, RT | 1 |
| Jorgetti, V | 1 |
| Moysés, RM | 1 |
| Xie, D | 1 |
| Hou, FF | 1 |
| Fu, BL | 1 |
| Zhang, X | 1 |
| Liang, M | 1 |
| Lymperopoulos, A | 1 |
| Rengo, G | 1 |
| Zincarelli, C | 1 |
| Kim, J | 1 |
| Koch, WJ | 1 |
| Kaji, K | 2 |
| Yoshiji, H | 2 |
| Kitade, M | 1 |
| Ikenaka, Y | 1 |
| Noguchi, R | 2 |
| Shirai, Y | 2 |
| Aihara, Y | 2 |
| Namisaki, T | 2 |
| Yoshii, J | 1 |
| Yanase, K | 1 |
| Tsujimoto, T | 1 |
| Kawaratani, H | 2 |
| Fukui, H | 2 |
| Holm, TM | 2 |
| Doyle, JJ | 2 |
| Kim, D | 1 |
| Schoenhoff, F | 2 |
| Cohn, RD | 1 |
| Loeys, BL | 1 |
| Thomas, CJ | 1 |
| Patnaik, S | 1 |
| Marugan, JJ | 1 |
| Aziz, H | 1 |
| Modiri, AN | 1 |
| Tang, R | 1 |
| Zhou, QL | 1 |
| Ao, X | 1 |
| Peng, WS | 1 |
| Veeraragoo, P | 1 |
| Tang, TF | 1 |
| Presta, P | 1 |
| Minutolo, R | 1 |
| Iodice, C | 1 |
| Comi, N | 1 |
| Casoria, V | 1 |
| Fuiano, L | 1 |
| Caglioti, C | 1 |
| Conte, G | 1 |
| Fuiano, G | 1 |
| Saeed, B | 1 |
| Mazloum, H | 1 |
| Askar, M | 1 |
| Wengrower, D | 1 |
| Zanninelli, G | 1 |
| Latella, G | 1 |
| Necozione, S | 1 |
| Metanes, I | 1 |
| Israeli, E | 1 |
| Lysy, J | 1 |
| Pines, M | 1 |
| Papo, O | 1 |
| Goldin, E | 1 |
| Arnold, SA | 1 |
| Rivera, LB | 1 |
| Carbon, JG | 1 |
| Toombs, JE | 1 |
| Chang, CL | 1 |
| Bradshaw, AD | 1 |
| Brekken, RA | 1 |
| Guerrot, D | 1 |
| Dussaule, JC | 1 |
| Mael-Ainin, M | 1 |
| Xu-Dubois, YC | 1 |
| Rondeau, E | 1 |
| Chatziantoniou, C | 1 |
| Placier, S | 1 |
| Van Eeden, S | 1 |
| Leipsic, J | 1 |
| Paul Man, SF | 1 |
| Sin, DD | 1 |
| Xiong, W | 1 |
| Meisinger, T | 1 |
| Knispel, R | 1 |
| Worth, JM | 1 |
| Baxter, BT | 1 |
| Couluris, M | 1 |
| Kinder, BW | 1 |
| Xu, P | 1 |
| Gross-King, M | 1 |
| Krischer, J | 1 |
| Panos, RJ | 1 |
| Tu, L | 1 |
| Handoko, ML | 1 |
| Rain, S | 1 |
| Ruiter, G | 1 |
| François, C | 1 |
| Schalij, I | 1 |
| Dorfmüller, P | 1 |
| Simonneau, G | 1 |
| Fadel, E | 1 |
| Perros, F | 1 |
| Boonstra, A | 1 |
| Postmus, PE | 1 |
| van der Velden, J | 1 |
| Humbert, M | 1 |
| Eddahibi, S | 1 |
| Guignabert, C | 1 |
| Douhara, A | 1 |
| Moriya, K | 1 |
| Leu, JG | 1 |
| Huang, CM | 1 |
| Kao, SJ | 1 |
| Jiang, WW | 1 |
| Devereux, RB | 2 |
| Palmieri, V | 2 |
| Liu, JE | 1 |
| Wachtell, K | 3 |
| Bella, JN | 2 |
| Boman, K | 1 |
| Gerdts, E | 2 |
| Nieminen, MS | 2 |
| Papademetriou, V | 2 |
| Dahlöf, B | 2 |
| Gerth, WC | 1 |
| Viberti, G | 1 |
| Hannedouche, T | 2 |
| Martinez-Castelao, A | 1 |
| Shahinfar, S | 5 |
| Carides, GW | 1 |
| Brenner, B | 1 |
| Suzuki, H | 1 |
| Iseki, K | 1 |
| Takishita, S | 1 |
| Souchet, T | 1 |
| Durand Zaleski, I | 1 |
| Rodier, M | 1 |
| Gaugris, S | 1 |
| Passa, P | 1 |
| Bakris, GL | 1 |
| Weir, MR | 1 |
| Shanifar, S | 1 |
| Douglas, J | 1 |
| van Dijk, DJ | 1 |
| Brenner, BM | 5 |
| Panos, J | 1 |
| Michelis, MF | 1 |
| DeVita, MV | 1 |
| Lavie, RH | 1 |
| Wilkes, BM | 1 |
| Appenroth, D | 1 |
| Beutinger, R | 1 |
| Lupp, A | 1 |
| Fleck, C | 1 |
| Onuigbo, MA | 1 |
| Takamitsu, Y | 1 |
| Mohanram, A | 1 |
| Keane, WF | 3 |
| Toto, RD | 1 |
| Tanaka, H | 1 |
| Suzuki, K | 1 |
| Nakahata, T | 1 |
| Tsugawa, K | 1 |
| Konno, Y | 1 |
| Tsuruga, K | 1 |
| Ito, E | 1 |
| Waga, S | 1 |
| Woo, KT | 1 |
| Lau, YK | 1 |
| Chan, CM | 1 |
| Wong, KS | 1 |
| Kowey, PR | 1 |
| Dickson, TZ | 1 |
| Luño, J | 1 |
| Wolf, G | 1 |
| Araujo, AQ | 1 |
| Arteaga, E | 1 |
| Ianni, BM | 1 |
| Buck, PC | 1 |
| Rabello, R | 1 |
| Mady, C | 1 |
| Burnier, M | 1 |
| Zanchi, A | 1 |
| Tuttle, JB | 1 |
| Wang, PX | 1 |
| Fan, MQ | 1 |
| Huang, CB | 1 |
| Feng, JY | 1 |
| Xiao, Y | 1 |
| Fang, ZQ | 1 |
| Zhang, YP | 1 |
| Fossum, E | 1 |
| Olsen, MH | 1 |
| Høieggen, A | 1 |
| Reims, HM | 1 |
| Kjeldsen, SE | 1 |
| Ibsen, H | 1 |
| Wan, Y | 1 |
| Julius, S | 1 |
| Lyle, PA | 1 |
| Osawa, H | 1 |
| Nakamura, N | 1 |
| Shirato, K | 1 |
| Nakamura, M | 2 |
| Shimada, M | 1 |
| Kumasaka, R | 1 |
| Murakami, R | 1 |
| Fujita, T | 1 |
| Yamabe, H | 1 |
| Okumura, K | 1 |
| Ruggenenti, P | 1 |
| McGrath, JC | 1 |
| Baumann, M | 1 |
| Janssen, BJ | 1 |
| Hermans, JJ | 1 |
| Peutz-Kootstra, C | 1 |
| Witzke, O | 1 |
| Smits, JF | 1 |
| Struijker Boudier, HA | 1 |
| Bro, S | 1 |
| Binder, CJ | 1 |
| Witztum, JL | 1 |
| Olgaard, K | 1 |
| Nielsen, LB | 1 |
| Suganuma, E | 1 |
| Babaev, VR | 1 |
| Motojima, M | 1 |
| Zuo, Y | 1 |
| Ayabe, N | 1 |
| Fogo, AB | 1 |
| Ichikawa, I | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Kon, V | 1 |
| Agha, A | 1 |
| Bashir, K | 1 |
| Anwar, E | 1 |
| Victor, RG | 1 |
| Anandanadesan, R | 1 |
| Gong, Q | 1 |
| Chipitsyna, G | 1 |
| Witkiewicz, A | 1 |
| Yeo, CJ | 1 |
| Arafat, HA | 1 |
| Dickstein, K | 1 |
| Chang, P | 1 |
| Willenheimer, R | 1 |
| Haunsø, S | 1 |
| Remes, J | 1 |
| Hall, C | 1 |
| Kjekshus, J | 1 |
| Makita, S | 1 |
| Yoshida, H | 1 |
| Hiramori, K | 1 |
| Helmy, A | 1 |
| Jalan, R | 1 |
| Newby, DE | 1 |
| Hayes, PC | 1 |
| Webb, DJ | 1 |
| Pagtalunan, ME | 1 |
| Olson, JL | 1 |
| Meyer, TW | 1 |
| Tuxen, C | 1 |
| de Simone, G | 1 |
| Mora-Macía, J | 1 |
| Cases, A | 1 |
| Calero, F | 1 |
| Barceló, P | 1 |
| Campistol, JM | 1 |
| Iñigo, P | 1 |
| Larios, S | 1 |
| Bescos, M | 1 |
| Oppenheimer, F | 1 |
| Cooper, ME | 1 |
| Mitch, WE | 1 |
| Snapinn, SM | 1 |
| Pierce, HL | 1 |
| Stevermer, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Losartan Effects on Emphysema Progression[NCT02696564] | Phase 4 | 220 participants (Actual) | Interventional | 2017-05-23 | Completed | ||
| A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | ||
| INHibition of the Renin Angiotensin System in Hypertrophic Cardiomyopathy and the Effect on Ventricular Hypertrophy - a Randomized Intervention Trial With Losartan.[NCT01447654] | Phase 2 | 130 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| [NCT00000609] | Phase 3 | 0 participants | Interventional | 1997-05-31 | Completed | ||
| A Multi-center, Double-Blind, Randomized, Parallel Group Study to Evaluate the Effects of Two Different Doses of Losartan on Morbidity and Mortality in Patients With Symptomatic Heart Failure Intolerant of ACE Inhibitor Treatment[NCT00090259] | Phase 3 | 3,834 participants (Actual) | Interventional | 2001-12-19 | Completed | ||
| Renoprotection in Early Diabetic Nephropathy in Pima Indians[NCT00340678] | Phase 3 | 170 participants (Actual) | Interventional | 1995-08-31 | Completed | ||
| CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)[NCT00555217] | Phase 3 | 1,448 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to It was stopped primarily because of safety concerns along with low conditional power to detect a treatment effect on the primary outcome.) | ||
| Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.[NCT00683124] | Phase 3 | 291 participants (Anticipated) | Interventional | 2008-07-31 | Recruiting | ||
| Renin Angiotensin System Blockage-DN (RASS)[NCT00143949] | Phase 2 | 285 participants (Actual) | Interventional | 1997-03-31 | Completed | ||
| Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus[NCT00419835] | Phase 4 | 80 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis[NCT01115426] | Phase 4 | 20 participants (Actual) | Interventional | 1997-01-31 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department.[NCT00437775] | 300 participants | Observational | 2007-01-31 | Recruiting | |||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)[NCT05037695] | Phase 4 | 40 participants (Anticipated) | Interventional | 2021-07-21 | Recruiting | ||
| Determinants of Diabetic Nephropathy in American Indians[NCT01878045] | 141 participants (Actual) | Observational | 2013-11-07 | Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from the first visit to the final visit in the participant's COPD Assessment Test (CAT) score. The CAT is an 8-item questionnaire assessing the impact of COPD on health status. CAT scores range from 0 to 40, with higher scores indicating a more severe impact of COPD on a patient's life. (NCT02696564)
Timeframe: 48 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Losartan | -0.18 |
| Placebo | 0.03 |
Change from the first visit to the final visit in participants' scores on the modified Medical Research Council dyspnea scale. The modified Medical Research Council dyspnea scale (mMRC) is a self-rating tool to measure how much breathlessness affects someone's day to day activities. Scores are between 0 and 4, with higher scores indicating more severe breathlessness. (NCT02696564)
Timeframe: 48 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Losartan | 0.01 |
| Placebo | 0.11 |
Change from the first visit to the final visit in a spirometry (breathing test) measure: forced expiratory volume in one second (FEV1). This test is performed after the participant is given bronchodilator medications. The FEV1 is compared to standard predicted values in the US population for each individual based on their height, gender, and ethnic group; the result is given as percent of predicted value. (NCT02696564)
Timeframe: 48 weeks
| Intervention | percentage of predicted value (Least Squares Mean) |
|---|---|
| Losartan | -2.60 |
| Placebo | -2.37 |
Change from the first visit to the final visit in a spirometry (breathing test) measure: forced expiratory volume in one second (FEV1). The test is administered without the participant taking any bronchodilator medication. The FEV1 is compared to standard predicted values in the US population for each individual based on their height, gender, and ethnic group; the result is given as percent of predicted value. (NCT02696564)
Timeframe: 48 weeks
| Intervention | percentage of predicted value (Least Squares Mean) |
|---|---|
| Losartan | -0.99 |
| Placebo | -0.54 |
"Change from the first visit to the final visit in participants' scores on the Patient-Reported Outcome Measures Information System (PROMIS) Physical Function assessment. The Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form 20a is a 20-item questionnaire used to indicate a patient's ability to perform activities of daily living, such as bathing, dressing, and commuting. Raw scores from this questionnaire are compared to a reference population to create a T-score. The general US population is the reference population. In this T-score metric, 50 indicates the population mean with a standard deviation of 10. Higher scores mean better outcomes (more ability to do activities of daily living)" (NCT02696564)
Timeframe: 48 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Losartan | 0.00 |
| Placebo | -1.04 |
Change from the first visit to the final visit in participants' scores on the activity-related questions on the St Georges Respiratory Questionnaire-COPD. The St George's Respiratory Questionnaire for COPD patients (SGRQ-C) is a 40-item questionnaire designed to measure impact on overall health, daily life, and perceived well-being in patients with COPD. The SGRQ-C includes three categories: Symptoms (frequency and severity), Activities caused or limited by breathlessness, and Impacts on social and psychological functioning caused by airways disease. The total score and scores for each category range from 0 to 100, with higher scores indicating more limitations. (NCT02696564)
Timeframe: 48 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Losartan | -0.66 |
| Placebo | 2.45 |
Change from the first visit to the final visit in participants' scores on the symptom-related questions on the St Georges Respiratory Questionnaire-COPD. The St George's Respiratory Questionnaire for COPD patients (SGRQ-C) is a 40-item questionnaire designed to measure impact on overall health, daily life, and perceived well-being in patients with COPD. The SGRQ-C includes three categories: Symptoms (frequency and severity), Activities caused or limited by breathlessness, and Impacts on social and psychological functioning caused by airways disease. The total score and scores for each category range from 0 to 100, with higher scores indicating more limitations. (NCT02696564)
Timeframe: 48 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Losartan | -6.19 |
| Placebo | -1.78 |
Change from the first visit to the final visit in participants' score on the St George's Respiratory Questionnaire - COPD. The St George's Respiratory Questionnaire for COPD patients (SGRQ-C) is a 40-item questionnaire designed to measure impact on overall health, daily life, and perceived well-being in patients with COPD. The SGRQ-C includes three categories: Symptoms (frequency and severity), Activities caused or limited by breathlessness, and Impacts on social and psychological functioning caused by airways disease. The total score and scores for each category range from 0 to 100, with higher scores indicating more limitations. (NCT02696564)
Timeframe: 48 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Losartan | -1.31 |
| Placebo | 1.20 |
change in percentage of voxels with density less than -950 Hounsfield Units (NCT02696564)
Timeframe: 48 weeks
| Intervention | percentage of voxels (Least Squares Mean) |
|---|---|
| Losartan | 1.35 |
| Placebo | 0.66 |
Change from the first visit to the final visit in participants' scores on the impact-related questions on the St Georges Respiratory Questionnaire-COPD. The St George's Respiratory Questionnaire for COPD patients (SGRQ-C) is a 40-item questionnaire designed to measure impact on overall health, daily life, and perceived well-being in patients with COPD. The SGRQ-C includes three categories: Symptoms (frequency and severity), Activities caused or limited by breathlessness, and Impacts on social and psychological functioning caused by airways disease. The total score and scores for each category range from 0 to 100, with higher scores indicating more limitations. (NCT02696564)
Timeframe: 48 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Losartan | -0.25 |
| Placebo | 1.35 |
"This measure assessed the number of exacerbations of chronic obstructive pulmonary disease in both the losartan and placebo treatment groups. Participants were asked about current and past exacerbations during each study visit. Exacerbations were defined as 2 or more worsening COPD symptoms lasting 3 or more consecutive days that required a new prescribed treatment. Each exacerbation was further classified as mild (requiring only a change in existing COPD medications),moderate (requiring a new prescription for a steroid and/or antibiotic), or severe (requiring a hospitalization for COPD symptoms)." (NCT02696564)
Timeframe: 48 weeks
| Intervention | exacerbation events (Number) | ||
|---|---|---|---|
| Mild exacerbation | Moderate exacerbation | Severe exacerbation | |
| Losartan | 3 | 41 | 7 |
| Placebo | 4 | 47 | 21 |
(NCT00090259)
Timeframe: Entire follow-up (median = 4.7 years)
| Intervention | Participants (Number) |
|---|---|
| Losartan 50 mg | 665 |
| Losartan 150 mg | 635 |
(NCT00090259)
Timeframe: Entire follow-up (median = 4.7 years)
| Intervention | Participants (Number) |
|---|---|
| Losartan 50 mg | 826 |
| Losartan 150 mg | 762 |
(NCT00090259)
Timeframe: Entire follow-up (median = 4.7 years)
| Intervention | Participants (Number) |
|---|---|
| Losartan 50 mg | 889 |
| Losartan 150 mg | 828 |
Cardiovascular hospitalization is defined as any hospitalization that may be attributed to a cardiovascular cause, including heart failure. (NCT00090259)
Timeframe: Entire follow-up (median = 4.7 years)
| Intervention | Participants (Number) |
|---|---|
| Losartan 50 mg | 1085 |
| Losartan 150 mg | 1037 |
(NCT00090259)
Timeframe: Entire follow-up (median = 4.7 years)
| Intervention | Participants (Number) |
|---|---|
| Losartan 50 mg | 503 |
| Losartan 150 mg | 450 |
(NCT00340678)
Timeframe: 6 years after first treatment
| Intervention | *10^6 cubic microns (Mean) |
|---|---|
| Normoalbuminuria Losartan | 5.4 |
| Normoalbuminuria Placebo | 5.6 |
| Microalbuminuria Losartan | 6.4 |
| Microalbuminuria Placebo | 7.0 |
Participants were monitored for up to 6 years. This is the number of participants who had a decline in GFR to less than or equal to 60 ml/min or to half the baseline value in subjects that enter the study with a GFR of less than 120 ml/min during the time of observation. (NCT00340678)
Timeframe: Up to 6 years
| Intervention | participants (Number) |
|---|---|
| Normoalbuminuria Losartan | 2 |
| Normoalbuminuria Placebo | 2 |
| Microalbuminuria Losartan | 1 |
| Microalbuminuria Placebo | 4 |
Time to the first event of reduction in estimated GFR of 30ml/min/1.73m*m in individuals w/a baseline estimated GFR >= 60 ml/min/1.73m*m, reduction in estimated GFR >50% in individuals w/ baseline estimated GFR <60ml/min/1.73m*m; ESRD or death. (NCT00555217)
Timeframe: From enrollemnt to time of first primary event, up to 4.5 years
| Intervention | participants (Number) |
|---|---|
| Combination of ARB and ACEI | 132 |
| Monotherapy ARB | 152 |
Time to the first event of reduction in estimated GFR of >50% (for individuals with baseline GFR <60) or reduction in GFR of >30 (for individuals with baseline GFR >= GFR 60) or ESRD. (NCT00555217)
Timeframe: From enrollment to time of first event, up to 4.5 years
| Intervention | participants (Number) |
|---|---|
| Combination of ARB and ACEI | 77 |
| Monotherapy ARB | 101 |
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
13 reviews available for losartan and Disease Exacerbation
| Article | Year |
|---|---|
Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
Topics: Adolescent; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih | 2018 |
Is losartan the true panacea for aneurysm disease? CON.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm, Thoracic; Disease Progression; Hu | 2010 |
Prostaglandin E1 for preventing the progression of diabetic kidney disease.
Topics: Albuminuria; Alprostadil; Diabetic Nephropathies; Disease Progression; Drugs, Chinese Herbal; Fosino | 2010 |
The relationship between lung inflammation and cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Diseas | 2012 |
[Evidence for the benefits of ACE inhibitors and AII antagonists in slowing progressive renal failure in diabetes].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Com | 2002 |
[Therapeutic strategy for patients with stable-stage chronic kidney failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2004 |
[Renin-angiotensin system in diabetic nephropathy].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2005 |
[The renin-angiotensin-aldosterone system -- more complex as previously thought].
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2005 |
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound | 2006 |
Losartan: lessons learned from the RENAAL study.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cli | 2006 |
Time to abandon microalbuminuria?
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; | 2006 |
Pathophysiology of target-organ disease: does angiotensin II remain the key?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2007 |
Role of transforming growth factor-beta1 in the progression of chronic allograft nephropathy.
Topics: Angiotensin II; Antihypertensive Agents; Biomarkers; Disease Progression; Endothelin-1; Humans; Kidn | 2001 |
30 trials available for losartan and Disease Exacerbation
| Article | Year |
|---|---|
Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative Losartan Effects on Emphysema Progression Clinical Trial.
Topics: Aged; Angiotensin Receptor Antagonists; Bronchodilator Agents; Disease Progression; Emphysema; Femal | 2022 |
The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.
Topics: Activities of Daily Living; Alzheimer Disease; Antihypertensive Agents; Atrophy; Blood Pressure Moni | 2018 |
Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aorti | 2018 |
Changes in Albuminuria But Not GFR are Associated with Early Changes in Kidney Structure in Type 2 Diabetes.
Topics: Adult; Albuminuria; Analysis of Variance; Biopsy, Needle; Diabetes Mellitus, Type 2; Diabetic Nephro | 2019 |
Control of home blood pressure with an amlodipine- or losartan-based regimen and progression of carotid artery intima-media thickness in hypertensive patients: the HOSP substudy.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2013 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mel | 2015 |
BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2015 |
Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Denmark; Disease | 2016 |
Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial.
Topics: Adult; Albumins; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; | 2016 |
Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Chemokine CCL2; | 2008 |
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus | 2009 |
Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Aneu | 2009 |
Renal and retinal effects of enalapril and losartan in type 1 diabetes.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2009 |
FGF-23 as a predictor of renal outcome in diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2011 |
High level of proteinuria during treatment with renin-angiotensin inhibitors is a strong predictor of renal outcome in nondiabetic kidney disease.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2011 |
Renin-angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10 year follow-up.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Di | 2011 |
Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project.
Topics: Aged; Aged, 80 and over; Disease Progression; Dyspnea; Exercise Test; Female; Humans; Idiopathic Pul | 2012 |
Efficacy and safety of losartan in patients with proteinuria.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Disease Progression; Female; Humans; Losartan; Male; | 2002 |
Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Disease Progression; Double-Blind | 2002 |
An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France.
Topics: Antihypertensive Agents; Blood Pressure; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Dia | 2003 |
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2003 |
Combined converting enzyme inhibition and angiotensin receptor blockade reduce proteinuria greater than converting enzyme inhibition alone: insights into mechanism.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Disease Progr | 2003 |
Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.
Topics: Aged; Anemia; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Pr | 2004 |
Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.
Topics: Adolescent; Antihypertensive Agents; Biopsy; Child; Creatinine; Disease Progression; Drug Therapy, C | 2004 |
Losartan and end-organ protection--lessons from the RENAAL study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Mellitus, Ty | 2005 |
Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Atenol | 2006 |
Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Diseas | 1995 |
Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Disease Progression; Echocardiography, Doppler; El | 2001 |
Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Creatinine; Diastole; Dis | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
69 other studies available for losartan and Disease Exacerbation
| Article | Year |
|---|---|
The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiotensin II Type 1 Receptor Blockers; Animals; Biopsy; Breast N | 2017 |
Interaction between interleukin‑6 and angiotensin II receptor 1 in the hypothalamic paraventricular nucleus contributes to progression of heart failure.
Topics: Animals; Corticotropin-Releasing Hormone; Disease Progression; Heart Failure; Interleukin-6; Losarta | 2017 |
Apocynin combined with drugs as coadjuvant could be employed to prevent and/or treat the chronic kidney disease.
Topics: Acetophenones; Adjuvants, Pharmaceutic; Animals; Antihypertensive Agents; Antioxidants; Blood Pressu | 2018 |
The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Aneurysm; Dilatation, Pathologic; Di | 2018 |
Angiotensin receptor signaling in sickle cell anemia has a reno-protective effect on urine concentrating ability but results in sickle glomerulopathy.
Topics: Adult; Anemia, Sickle Cell; Angiotensin II Type 1 Receptor Blockers; Animals; Captopril; Child; Dise | 2018 |
Post-stroke losartan and captopril treatments arrest hemorrhagic expansion in SHRsp without lowering blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 2018 |
Losartan attenuates progression of osteoarthritis in the synovial temporomandibular and knee joints of a chondrodysplasia mouse model through inhibition of TGF-β1 signaling pathway.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Cartilage, Articular; Cells, Cu | 2019 |
Losartan delays the progression of streptozotocin-induced diabetic cataracts in albino rats.
Topics: Administration, Oral; Administration, Topical; Aldehyde Reductase; Angiotensin II Type 1 Receptor Bl | 2019 |
[Prescription of renin-angiotensin-aldosterone system blockers in patients with stage 3 chronic kidney disease].
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Creatinine; D | 2019 |
Paternal fibrillin-1 mutation transmitted to an affected son with neonatal marfan syndrome: the importance of early recognition.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Dilatation, Pathologic; | 2014 |
Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Aneurysm; Cells, Cul | 2014 |
Angiotensin II promotes the progression of human gastric cancer.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Line, Tumor; Cell Movement; C | 2014 |
Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy.
Topics: Actins; Animals; Apoptosis; bcl-2-Associated X Protein; Collagen Type I; Dimethyl Sulfoxide; Disease | 2014 |
Interaction between interleukin-1 beta and angiotensin II receptor 1 in hypothalamic paraventricular nucleus contributes to progression of heart failure.
Topics: Animals; Corticotropin-Releasing Hormone; Disease Models, Animal; Disease Progression; gamma-Aminobu | 2014 |
Dual targeting of angiotensin receptors (AGTR1 and AGTR2) in epithelial ovarian carcinoma.
Topics: Angiotensin II Type 1 Receptor Blockers; Carcinoma, Ovarian Epithelial; Cells, Cultured; Disease Pro | 2014 |
Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Bisoprolol | 2014 |
Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cholinesterase Inhibitors; Chronic Disease; Diseas | 2014 |
Combining use of captopril and losartan attenuates the progress of Streptococcus pneumoniae-induced tympanosclerosis through the suppression of TGF-β1 expression.
Topics: Animals; Blotting, Western; Calcinosis; Calcium; Captopril; Disease Models, Animal; Disease Progress | 2014 |
Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies, Neutralizing; Aorta, Thoracic; Aortic | 2015 |
Th-17 cell activation in response to high salt following acute kidney injury is associated with progressive fibrosis and attenuated by AT-1R antagonism.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultur | 2015 |
Atherosclerosis, neoatherosclerosis, and vascular disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Aortic Valve Stenosis; Cardiovascular Dise | 2015 |
Attenuation of the progression of articular cartilage degeneration by inhibition of TGF-β1 signaling in a mouse model of osteoarthritis.
Topics: Animals; Cartilage, Articular; Chondrogenesis; Disease Models, Animal; Disease Progression; Female; | 2015 |
Therapeutic efficacy of bone marrow derived mesenchymal stromal cells versus losartan on adriamycin-induced renal cortical injury in adult albino rats.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Disease Models, Animal; Disease Progression | 2016 |
Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Decision Support Techniques; Disease | 2016 |
Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Decision Support Techniques; Disease | 2016 |
Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Decision Support Techniques; Disease | 2016 |
Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Decision Support Techniques; Disease | 2016 |
Chlorothiazide-induced photoaggravation of psoriatic lesion during narrowband ultraviolet B treatment in a case of psoriasis vulgaris.
Topics: Aged; Disease Progression; Drug Combinations; Female; Ficusin; Humans; Hydrochlorothiazide; Hyperten | 2017 |
Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Targeting TGF-beta and the extracellular matrix in Marfan's syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Child; Disease Progression; Extracellular Matrix; Fibrillin | 2008 |
Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antineoplastic Agents; Bl | 2009 |
Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression.
Topics: Animals; Antihypertensive Agents; Biomarkers; Chronic Disease; Disease Models, Animal; Disease Progr | 2009 |
Battle against the renin-angiotensin system: help from an unexpected party.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetic Nephropathies; Disease Models, Animal; Di | 2009 |
Heme oxygenase-1 inducer hemin attenuates the progression of remnant kidney model.
Topics: Animals; Bone Morphogenetic Protein 7; Caspase 3; Disease Progression; Enzyme Induction; Fibrosis; G | 2009 |
V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antidiur | 2009 |
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Topics: Albuminuria; Amides; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic | 2009 |
Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultured; Disease Progression; Drug Deliver | 2010 |
Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Crea | 2010 |
Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Creatinine; Diabe | 2010 |
Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels.
Topics: Adrenal Glands; Aldosterone; Animals; Arrestins; beta-Arrestin 1; beta-Arrestins; Cell Line; Disease | 2011 |
Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Topics: Administration, Oral; Angiogenesis Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blocke | 2011 |
Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.
Topics: Animals; Anthracenes; Aorta; Aortic Aneurysm; Diphenylamine; Disease Models, Animal; Disease Progres | 2011 |
Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2011 |
Fosinopril and losartan regulate klotho gene and nicotinamide adenine dinucleotide phosphate oxidase expression in kidneys of spontaneously hypertensive rats.
Topics: Animals; Disease Progression; Fosinopril; Gene Expression Regulation, Enzymologic; Glucuronidase; Hy | 2011 |
Spontaneous remission of post-transplant recurrent focal and segmental glomerulosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Child; Disease Pr | 2011 |
Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Colitis; Disease Models, Animal; Disease Progressi | 2012 |
Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Progression; Extracellular Matrix; Losarta | 2012 |
Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy.
Topics: Animals; Biomarkers; Blood Pressure; Cell Adhesion Molecules; Disease Progression; Gene Expression R | 2012 |
MMP-2 regulates Erk1/2 phosphorylation and aortic dilatation in Marfan syndrome.
Topics: Animals; Aorta, Thoracic; Disease Progression; Doxycycline; Drug Therapy, Combination; Losartan; MAP | 2012 |
Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Case-Control Studies; Cells, Cultured; Disease Pro | 2012 |
Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Communication; Disease Models | 2013 |
Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
Topics: Angiotensin II Type 1 Receptor Blockers; Cost of Illness; Cost Savings; Cost-Benefit Analysis; Diabe | 2002 |
Progression of renal failure delayed by use of losartan in a case of IgA nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Chronic Disease; Creatinine; Disea | 2002 |
Effects of a therapy with losartan and quinaprilat on the progression of chronic renal failure in rats after a single dose of uranyl nitrate or 5/6 nephrectomy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Disease | 2003 |
Achieved vs initial blood pressure in predicting renal outcomes.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2004 |
ATRA therapy restores normal renal function and renal reserve and prevents renal failure.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Creatinine; Disease Progres | 2005 |
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; C | 2005 |
Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Flow Velocity; Cardiom | 2005 |
Blockade of angiotensin II and aging: is the spontaneously hypertensive rat a suitable model?
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Diseases; Cardiovascular Sys | 2006 |
Effect of losartan on slowing progression of chronic allograft nephropathy.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Creatinine; Disease Progression; F | 2005 |
Increased vascular angiotensin II binding capacity and ET-1 release in young cardiomyopathic hamsters.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Binding, Competit | 2006 |
Losartan, an angiotensin-II receptor antagonist, retards the progression of advanced renal insufficiency.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Creatinine; | 2006 |
Simply removing pressure doesn't work, but youthful drug-taking prevents hereditary mid-life failure.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood | 2007 |
Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age.
Topics: Age Factors; Aging; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; C | 2007 |
Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodi | 2007 |
Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aortic Di | 2007 |
Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diabe | 2007 |
Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blotting, Western; Carcinoma, Pancreatic Du | 2008 |
Effect of angiotensin II receptor blocker on angiotensin II stimulated DNA synthesis of cultured human aortic smooth muscle cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Aorta; Arteriosclerosis; Biphenyl Compounds; Cell | 1995 |
Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Blood Vessels; Disease Progression; Dose-Response Re | 2000 |
Contribution of angiotensin II to late renal injury after acute ischemia.
Topics: Acute Disease; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Progressio | 2000 |
Does losartan (Cozaar) slow the progression of renal disease in patients with type 2 diabetes and nephropathy?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Confidence Intervals; Diabetes Mellitus, Type | 2001 |